Eye drug delivery device
By designing an ophthalmic drug delivery device, the problem of poor compliance with traditional ophthalmic drug delivery is solved, precise control and continuous drug delivery is achieved, and it is suitable for chronic eye disease management and post-ophthalmic recovery.
Patent Information
- Application Number
- CN202510674700.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-23
- Publication Date
- 2025-08-15
Smart Images
Figure CN120478037A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of ophthalmic medical instruments, in particular to an eye medication device. Background Art
[0002] Ocular diseases such as dry eye, corneal damage, and glaucoma are common in clinical practice. Traditional treatments often involve administering drugs through artificial eye drops or ointments. However, this approach has the following drawbacks: drug administration frequency is significantly affected by human factors, patient compliance is low, and problems such as leaked drops, insufficient or excessive dosage can occur, compromising efficacy. Furthermore, continuous drug delivery is difficult to achieve at night or in special circumstances. Therefore, there is an urgent need for an intelligent, convenient, and highly controllable ocular drug delivery device to improve the stability and effectiveness of ocular drug delivery. Summary of the Invention
[0003] In view of the above-mentioned shortcomings of the prior art, the purpose of the present invention is to provide an ocular drug delivery device to achieve precise control of the drug solution delivered to the eye, thereby solving the problems of unstable manual drug delivery and poor compliance in the prior art.
[0004] To achieve the above-mentioned and other related objects, the present invention provides an ocular drug delivery device, including, but not limited to: a drug liquid transmission system, a drug liquid delivery system, a control module, and a drug liquid storage system;
[0005] The liquid medicine transmission system includes, but is not limited to, a liquid medicine transmission pipeline, wherein both ends of the liquid medicine transmission pipeline are connected to a liquid inlet port and a liquid outlet port respectively;
[0006] The liquid medicine storage system is used to store liquid medicine;
[0007] The drug liquid delivery system provides power for drug liquid delivery;
[0008] The control module includes, but is not limited to, a control device and a power supply connected to the control device, wherein the control device is connected to the drug liquid delivery system; the control device controls the drug liquid delivery system to drive the drug liquid in the drug liquid storage system to be transported outward through the drug liquid transmission pipeline.
[0009] Preferably, the ocular drug delivery device is arranged in an in vitro, in vivo or partially in vivo manner; the liquid outlet port of the drug delivery pipeline contacts the drug delivery area;
[0010] The in vitro method is to place the ocular drug delivery device as a whole outside the human body;
[0011] The in-vivo method is to implant the ocular drug delivery device as a whole into the human body;
[0012] The partially intracorporeal type is a method in which a portion of the ocular drug delivery device is implanted inside the human body, and the other portion of the ocular drug delivery device is placed outside the human body.
[0013] Furthermore, when the ocular drug delivery device is provided in an intracorporeal or partially intracorporeal manner, the drug delivery area contacted by the liquid outlet port of the drug delivery pipeline includes, but is not limited to, the eye, eye-related tissue area, or periocular tissue area; the drug delivery area contacted by the liquid outlet port of the drug delivery pipeline includes, but is not limited to: the eyelid, lacrimal duct, lacrimal sac, lacrimal gland, lacrimal punctum, canthus, palpebral margin, conjunctiva, meibomian gland outlet area, and / or the area surrounding the limbus;
[0014] When the ocular drug delivery device is set up in vitro, the drug delivery area contacted by the liquid outlet port of the drug delivery pipeline includes, but is not limited to, the eye and eye-related tissue areas; the drug delivery area contacted by the liquid outlet port of the drug delivery pipeline is the eye area, and the characteristic of the eye area is that the contact between the liquid outlet port and the area has a smaller risk of causing a foreign body sensation in the user, and the eye area includes, but is not limited to: the corner of the eye, the eyelid margin, the conjunctiva, the meibomian gland outlet area and / or the area around the corneal limbus.
[0015] Furthermore, when a portion of the ocular drug delivery device is implanted inside the human body, the tissues through which the ocular drug delivery device is implanted include, but are not limited to: the nasal cavity, nasolacrimal duct, lacrimal sac, lacrimal duct, postauricular area, temporal soft tissue, subcutaneous tissue below the zygomatic bone, inner side of the upper eyelid, inner side of the lower eyelid, lacrimal gland, or lacrimal punctum entrance.
[0016] Preferably, the drug delivery method of the ocular drug delivery device includes, but is not limited to, any one of the following:
[0017] A1. The drug delivery system provides power to deliver the drug;
[0018] A2. The drug delivery system provides power to transport the drug. At the same time, the position of the eye drug delivery device can be adjusted to form a height difference between the liquid level of the drug storage system and the eye area, and the height difference causes static pressure to assist in drug delivery.
[0019] Furthermore, the drug delivery system provides power to deliver the drug, including, but not limited to, any of the following:
[0020] B1. The drug liquid delivery system is disposed in the drug liquid storage system, and the drug liquid delivery system applies pressure to the drug liquid to push the drug liquid out;
[0021] B2, the drug delivery system pushes the drug in the drug storage system into the drug transmission system through a diaphragm structure or a piston structure;
[0022] B3. The drug delivery system provides driving force, and the drug delivery system transports the drug to the eye area through the drug transmission system.
[0023] Preferably, the control device controls the liquid medicine delivery system in a manner including, but not limited to: a wireless remote control mode, a wired connection mode and / or an independent operation mode;
[0024] The wireless remote control method includes, but is not limited to: optical communication, acoustic wave communication and / or electromagnetic wave communication;
[0025] The wired connection method includes, but is not limited to: connecting a serial communication port and / or a parallel communication port to a terminal device, or connecting a serial communication port and / or a parallel communication port to a host computer;
[0026] The independent operation mode is that the control device operates independently under preset parameter conditions without external input, thereby realizing the liquid medicine delivery control function.
[0027] Preferably, the drug liquid delivery system and the drug liquid transmission system are directly connected, or the drug liquid delivery system and the drug liquid transmission system are indirectly connected.
[0028] Preferably, the liquid medicine storage system can be a disposable or reusable structure, and the structure of the liquid medicine storage system includes, but is not limited to: a sealed structure, a replaceable liner structure, a flexible liquid storage bag structure and / or a rigid liquid medicine box structure.
[0029] Preferably, the drug solution includes, but is not limited to, finished drugs approved by the State Food and Drug Administration, hospital preparations that comply with relevant regulatory requirements, or liquid preparations that meet medical use standards; the drug solution includes, but is not limited to autologous serum preparations, single drug solutions or compound drug solutions; the single drug solution includes, but is not limited to, one active ingredient; the compound drug solution includes, but is not limited to, two or more drugs.
[0030] As described above, the ocular drug delivery device of the present invention has the following beneficial effects: the control device controls the drug delivery system to drive the drug in the drug storage system, and transports the drug outward through the drug transmission pipeline. The liquid outlet port of the drug transmission pipeline contacts the drug delivery area to achieve drug delivery to the eye; the ocular drug delivery device improves the accuracy of drug delivery, the safety of drug delivery and / or user compliance, and is suitable for the management of chronic eye diseases and postoperative recovery of ophthalmology. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Schematic diagram of the structure of the eye drug delivery device of this embodiment.
[0032] Figure 2 Schematic diagram of the structure of the liquid outlet port of the eye drug delivery device of this embodiment contacting the eye drug delivery area.
[0033] Figure 3 Schematic diagram of the structure of the eye drug delivery device of this embodiment provided with a nasolacrimal duct adapter.
[0034] Figure 4 This is a schematic diagram of the structure of the ocular drug delivery device of this embodiment in which the drug delivery system, control module and drug storage system form an integrated structure, and the integrated structure is set on glasses.
[0035] Figure 5 This is a schematic diagram of the structure of the ocular drug delivery device of this embodiment in which the drug delivery system, control module and drug storage system form an integrated structure, and the integrated structure is set on a support mechanism.
[0036] Figure 6 This is a schematic diagram of the structure of the ocular drug delivery device of this embodiment in which the drug delivery system, control module and drug storage system form an integrated structure, and the integrated structure is set on a hook.
[0037] Figure 7 This is a schematic diagram of the structure of the ocular drug delivery device of this embodiment in which the drug delivery system, control module and drug storage system form an integrated structure, and the integrated structure is set on a medical instrument.
[0038] Figure 8 This is a schematic structural diagram of the liquid drug delivery system of the eye drug delivery device of this embodiment when it is arranged on the structural support.
[0039] Figure 9 This is a schematic structural diagram of the eye medication delivery system of this embodiment when it is arranged on the buckle slot.
[0040] Figure 10 This is a structural diagram of the liquid drug delivery system of the eye drug delivery device of this embodiment being connected to the control module through the housing slot.
[0041] Figure 11 This is a schematic structural diagram of the liquid drug delivery system of the eye drug delivery device of this embodiment connected to the control module via a flexible bracket.
[0042] Figure 12 This is a structural diagram of the liquid medicine delivery system of the ocular drug delivery device of this embodiment, which uses a diaphragm structure to push the liquid medicine in the liquid medicine storage system into the liquid medicine transmission system.
[0043] Figure 13 This is a structural diagram of the eye medication device of this embodiment in which the drug liquid storage system and the control module are connected via a flexible wire.
[0044] Figure 14 This is a schematic diagram of the integrated structure of the drug delivery system, control module and drug storage system of the eye drug delivery device placed on the temporal side of a person in this embodiment, with the liquid outlet port of the integrated structure leading to the lacrimal gland.
[0045] Figure 15 This is a schematic diagram of an ocular drug delivery device placed above a person's eye in this embodiment, in which the drug delivery system, control module and drug storage system form an integrated structure, and the liquid outlet port of the integrated structure leads to the lacrimal gland.
[0046] Figure 16 This is a schematic diagram of the ocular drug delivery device of this embodiment, in which the drug delivery system, control module and drug storage system form an integrated structure, and the liquid outlet port of the integrated structure is connected to the lower lacrimal punctum.
[0047] Figure 17 This is a schematic diagram showing that the drug delivery system, control module and drug storage system of the ocular drug delivery device of this embodiment form an integrated structure, and the liquid outlet port of the integrated structure is connected to the lower eyelid.
[0048] Explanation of Figure Numbers
[0049] 1. Liquid drug delivery system
[0050] 101 liquid transmission pipeline
[0051] 102 liquid inlet port
[0052] 103 liquid outlet port
[0053] 2. Drug delivery system
[0054] 3 Control Module
[0055] 4. Liquid storage system
[0056] 5. Nasolacrimal duct adapter
[0057] 6 interfaces
[0058] 7Integrated structure
[0059] 8 glasses
[0060] 9 bracket mechanism
[0061] 10 snap-on structure
[0062] 11 hooks
[0063] 12 Medical Equipment
[0064] 13 adsorption area
[0065] 14 structural supports
[0066] 15 snap slots
[0067] 16 housing slots
[0068] 17 Flexible bracket
[0069] 18 diaphragm structure
[0070] 19 flexible wire DETAILED DESCRIPTION
[0071] The following describes the implementation of the present invention through specific embodiments. People skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0072] Please refer to the accompanying drawings. It should be noted that the structures, proportions, sizes, etc. illustrated in the drawings of this specification are only used to match the contents disclosed in the specification for people familiar with this technology to understand and read, and are not used to limit the limiting conditions for the implementation of the present invention. Therefore, they have no substantive technical significance. Any modification of the structure, change in the proportional relationship, or adjustment of the size should still fall within the scope of the technical content disclosed by the present invention without affecting the efficacy and purpose that can be achieved by the present invention. At the same time, the terms such as "upper", "lower", "left", "right", "middle" and "one" quoted in this specification are only for the convenience of description, and are not used to limit the scope of the implementation of the present invention. Changes or adjustments in their relative relationships should also be regarded as the scope of the implementation of the present invention without substantially changing the technical content.
[0073] like Figures 1 to 17 As shown, the ocular drug delivery device of this embodiment includes, but is not limited to: a drug liquid transmission system 1, a drug liquid delivery system 2, a control module 3 and a drug liquid storage system 4;
[0074] The liquid medicine transmission system 1 includes, but is not limited to, a liquid medicine transmission pipeline 101 , wherein both ends of the liquid medicine transmission pipeline 101 are connected to a liquid inlet port 102 and a liquid outlet port 103 respectively;
[0075] The liquid medicine storage system 4 is used to store liquid medicine; the liquid medicine storage system 4 is connected to the liquid inlet port 102 of the liquid medicine transmission pipeline 101, or the liquid medicine delivery system 2 is connected to the liquid inlet port 102 of the liquid medicine transmission pipeline 101;
[0076] The drug liquid delivery system 2 provides power for drug liquid delivery;
[0077] The control module 3 includes, but is not limited to, a control device and a power supply connected to the control device, and the control device is connected to the drug liquid delivery system 2; the control device controls the drug liquid delivery system 2 to drive the drug liquid in the drug liquid storage system 4 to be transported outward through the drug liquid transmission pipeline 101.
[0078] In the ophthalmic drug delivery device of the present invention, the control device controls the drug delivery system 2 to drive the drug in the drug storage system 4, and transports the drug outward through the drug transmission pipeline 101. The liquid outlet port 103 of the drug transmission pipeline 101 contacts the drug delivery area to achieve drug delivery to the eye; the ophthalmic drug delivery device improves the accuracy of drug delivery, the safety of drug delivery and user compliance, and is suitable for the management of chronic eye diseases and postoperative recovery of ophthalmology.
[0079] The ocular drug delivery device can be flexibly configured in terms of structure and path according to the clinical scenario and patient needs. The ocular drug delivery device can be configured in an in vitro, in vivo, or partially in vivo manner. The liquid outlet port 103 of the liquid drug delivery line 101 contacts the drug delivery area.
[0080] In vitro, the entire ocular drug delivery device is placed outside the human body, with only the liquid outlet port 103 of the drug delivery line 101 contacting the drug delivery area. The drug delivery area includes, but is not limited to, the eye and eye-related areas. The eye and eye-related areas include, but are not limited to: the canthus, eyelid margin, conjunctiva, meibomian gland outlet area, and / or the area around the corneal limbus. The meibomian gland outlet area is the area of the eyelid margin near the root of the eyelashes. When the ocular drug delivery device is placed outside the human body, the device can be used stably in vitro in a variety of ways. The methods of use of the ocular drug delivery device include, but are not limited to: wearable, bracket-type, mountable, and / or integrated with a medical instrument module.
[0081] The wearable type is to set the eye drug delivery device on a wearable device.
[0082] Wearable devices include, but are not limited to: glasses, eye masks, ear hangings, headbands, forehead bands, nose bridge fixings, face masks, face patches, chest hanging clips and / or clothing clips, and the corresponding wearable types include, but are not limited to: glasses type, eye mask type, ear hanging type, headband type, forehead band type, nose bridge fixings, face masks type, face patches, chest hanging clips and / or clothing clips. Figure 4 As shown, the drug delivery system 2, the control module 3 and the drug storage system 4 form an integrated structure 7, and the wearable device is glasses 8, and the integrated structure 7 is set on the temples of the glasses.
[0083] The bracket type is to place the eye drug delivery device on a bracket mechanism; the bracket mechanism includes, but is not limited to: a desktop bracket, a multi-joint mechanical arm bracket, an adsorption bracket and / or a magnetic bracket, etc. Figure 5 As shown, the drug delivery system 2, the control module 3 and the drug storage system 4 form an integrated structure 7, which is disposed on a support mechanism 9. A buckle structure 10 is provided on the top of the integrated structure 7.
[0084] The mounting type is to place the ocular drug delivery device on a mounting mechanism; the mounting mechanism includes, but is not limited to, a hook or a hanger. Figure 6 As shown, the drug delivery system 2 , the control module 3 and the drug storage system 4 form an integrated structure 7 , and the mounting mechanism includes, but is not limited to: a hook 11 , and the integrated structure 7 is set on the hook 11 .
[0085] The medical instrument module integration is to set the eye drug delivery device on a medical instrument, which includes, but is not limited to: an ophthalmic surgical device, a nebulizer treatment device, a meibomian gland dysfunction treatment device and / or a smart wearable medical terminal. Figure 7 As shown, the drug delivery system 2 , the control module 3 and the drug storage system 4 form an integrated structure 7 , which is disposed on a medical instrument 12 . The medical instrument 12 has an adsorption area 13 , on which the integrated structure 7 is disposed.
[0086] When the ophthalmic drug delivery device is set up in an extracorporeal manner, and the part of the ophthalmic drug delivery device that is located outside the human body is used in a wearable manner, the control module 3, the drug storage system 4, and the drug delivery system 2 of the ophthalmic drug delivery device are located on the side of the eye mask, the temple of the glasses, or the headband; when the part of the ophthalmic drug delivery device that is located outside the human body is used in a bracket manner, the control module 3, the drug storage system 4, and the drug delivery system 2 of the ophthalmic drug delivery device are located on the bracket mechanism or the bracket arm of the bracket mechanism, and the ophthalmic drug delivery device can be integrated into the bracket mechanism or be an independent detachable module; when the part of the ophthalmic drug delivery device that is located outside the human body is used in a mounted manner, the control module 3, the drug storage system 4, and the drug delivery system 2 of the ophthalmic drug delivery device are installed on the user's head, chest, external hook or hanger and other supporting structures in the form of ear hanging, clamping or wearing; when the part of the ophthalmic drug delivery device that is located outside the human body is used in a medical instrument module integrated manner, the control module 3, the drug storage system 4, and the drug delivery system 2 of the ophthalmic drug delivery device can be embedded in the medical instrument or diagnostic equipment, or independently installed outside the equipment. The control module 3 , the drug liquid storage system 4 and the drug liquid delivery system 2 may also be integrated into one body and combined with the supporting component.
[0087] The in-vivo method involves implanting the entire ocular drug delivery device into the human body. The ocular drug delivery device is implanted into the human body via minimally invasive surgery. The drug delivery system 1 can be arranged along a subcutaneous path so that the outlet port 103 of the drug delivery line 101 contacts a drug delivery area including, but not limited to, the eye, an eye-related tissue area, or an eye periocular tissue area. The drug delivery area includes, but is not limited to, the eyelid, lacrimal duct, lacrimal sac, lacrimal gland, lacrimal punctum, canthus, eyelid margin, conjunctiva, meibomian gland outlet area, and / or the area surrounding the corneal limbus. The meibomian gland outlet area is the area of the eyelid margin near the root of the eyelashes.
[0088] Figure 14The diagram shows an integrated structure of a drug delivery system, a control module and a drug storage system of an eye drug delivery device placed on the temporal side of a person according to the present invention, wherein the liquid outlet port of the integrated structure is connected to the lacrimal gland. Figure 15 The diagram is a schematic diagram of an ocular drug delivery device placed above a human eye according to the present invention, in which a drug delivery system, a control module and a drug storage system form an integrated structure, and a liquid outlet port of the integrated structure is connected to the lacrimal gland. Figure 16 The diagram is a schematic diagram showing that the drug delivery system, control module and drug storage system of the ocular drug delivery device of the present invention form an integrated structure, and the liquid outlet port of the integrated structure is connected to the lower lacrimal punctum. Figure 17 The diagram is a schematic diagram showing that the drug delivery system, control module and drug storage system of the ocular drug delivery device of the present invention form an integrated structure, and the liquid outlet port of the integrated structure is connected to the lower eyelid.
[0089] When the ocular drug delivery device is placed in the human body as a whole, the device can be stably used in the body in a variety of ways. The methods of implanting the ocular drug delivery device in the human body include, but are not limited to: tissue suture fixation, subcutaneous pocket embedding, claw structure embedding, anchor structure embedding, self-expanding support structure, intra-capsular modular design and / or medical adhesive fixation;
[0090] The tissue suture fixation type is commonly used in existing surgeries such as glaucoma drainage valve implantation and pacemaker implantation; the subcutaneous pocket embedding type is commonly used in existing surgeries such as long-acting sustained-release drug implants and insulin pump implantation; the hook structure embedded type and the anchoring structure embedded type are commonly used in existing lacrimal stent anchoring and nickel-titanium alloy barb design, such as SmartPlug tear plug; the self-expanding support structure is commonly used in surgeries such as nasolacrimal duct stents, glaucoma microstents, and carotid artery stents; the intra-capsular modular design is commonly used in surgeries such as artificial vitreous balloon (FCVB) and suprachoroidal drug delivery system; the medical glue fixation type is commonly used in existing surgeries such as skin incision closure, corneal perforation closure, and conjunctival filtration bleb reinforcement.
[0091] The ocular drug delivery device of this embodiment is suitable for, but not limited to, long-term medication use in patients with chronic diseases, such as severe dry eyes and autoimmune ocular surface lesions; the ocular drug delivery device can eliminate the need for frequent manual drug drops and is suitable for patients with poor compliance, such as elderly patients or children; the ocular drug delivery device can maintain stable drug control in patients who need postoperative medication, such as corneal transplant patients and glaucoma patients; and patients who need continuous drug delivery to the eyes in cases of corneal or other ocular surface damage, infection, etc.
[0092] When the ocular drug delivery device is installed in vivo, the methods of connection between the ocular drug delivery device and various internal components are: when using tissue suturing fixation, it is fixed with common surgical sutures; when using subcutaneous pocket embedding, the ocular drug delivery device is surgically implanted in a subcutaneous cavity or pocket; when using claw structure embedding or anchoring structure embedding, the ocular drug delivery device is embedded and fixed to a specific tissue location by mechanical attachment; when using a self-expanding support structure, the ocular drug delivery device relies on shape memory alloy or biocompatible elastic material to automatically expand to the target anatomical site after implantation; when using an implantable capsule modular design, the ocular drug delivery device is encapsulated in a pocket or cavity made of a biocompatible material and implanted near the target tissue; when using medical adhesive fixation, the ocular drug delivery device is fixed to the tissue surface or implantation area using medical biological adhesive. To achieve the replenishment of the drug solution during long-term use of the ocular drug delivery device, the drug solution storage system 4 can be, but is not limited to: a self-sealing structure accessible by puncture, or a detachable small pocket design. The self-sealing structure may be a closed structure, which allows the fluid inlet to be connected when the needle enters to replenish the liquid medicine, and the fluid inlet is automatically closed after the needle is pulled out, blocking the access to the outside world. The self-sealing structure can also be selected from materials with good biocompatibility such as medical-grade silicone and polyurethane. When the liquid medicine is exhausted, it can be injected subcutaneously using a matching syringe to puncture from outside the body to reach the internal eye drug delivery device, and then the liquid reservoir can be replenished through the self-sealing structure of the device without removing the implanted device. The puncture operation can be completed by medical professionals in an outpatient environment, and the operation process is simple, less invasive, and has good repeatability. The detachable small capsule belt can be replaced through a minimally invasive incision. Dressing change method: completed in an outpatient clinic or day surgery, using minimally invasive surgical tools to remove the old module and replace it with a new capsule bag.
[0093] The ocular drug delivery device is provided in a partially internal manner; in a partially internal manner, one portion of the ocular drug delivery device is implanted inside the human body, and the other portion is placed outside the human body;
[0094] When the ocular drug delivery device is configured as a partially internal body device, the drug delivery area contacted by the liquid outlet port 103 of the drug delivery pipeline 101 is the eye, an eye-related tissue area, or an eye-peripheral tissue area.
[0095] The liquid drug transmission system 1 or part of the liquid drug transmission system 1 in the ocular drug delivery device is implanted or placed in the body; or, the liquid drug transmission system 1 and the liquid drug delivery system 2 and / or the control module 3 are implanted or placed in the body; part of the liquid drug transmission system 1 and the liquid drug delivery system 2 and / or the control module 3 are implanted or placed in the body.
[0096] One end of the drug liquid transmission system 1 enters the body through the nasal cavity, and the other end of the drug liquid transmission system 1 is connected to the drug liquid delivery system 2, control module 3 and drug liquid storage system 4 outside the body; or one end of the drug liquid transmission system 1 reaches the periocular tissue area through the subcutaneous tissue, and the other end of the drug liquid transmission system 1 passes through the area behind the ear, temporal region, etc. to connect to the external device.
[0097] The drug delivery area includes, but is not limited to: eyelids, lacrimal ducts, lacrimal sacs, lacrimal glands and / or lacrimal puncta. The drug delivery system 1 can flexibly select the implantation path according to the patient's usage scenario and treatment needs. The implantation path of the eye drug delivery device includes, but is not limited to: nasal cavity, nasolacrimal duct, lacrimal sac, lacrimal duct, postauricular area, temporal soft tissue, subcutaneous tissue below the zygomatic bone, inner side of the upper eyelid, inner side of the lower eyelid, lacrimal gland, or lacrimal puncta entrance and other locations. The part of the device placed outside the body can be used stably in vitro in a variety of ways. The use of the part of the eye drug delivery device outside the human body includes, but is not limited to: wearable, bracket-type, mount-type and / or medical instrument module integrated type; the wearable type is to set the eye drug delivery device on a wearable device.
[0098] If the wearable device is: glasses, eye masks, ear hanging parts, headbands, forehead bands, nose bridge fixing parts, face masks, face patches, chest hanging clips and / or clothing clips, then the corresponding wearable types include, but are not limited to: glasses type, eye mask type, ear hanging type, headband type, forehead band type, nose bridge fixing parts, face masks type, face patches, chest hanging clips and / or clothing clips. Figure 4 As shown, the drug delivery system 2, the control module 3 and the drug storage system 4 form an integrated structure 7, and the wearable device is glasses 8, and the integrated structure 7 is set on the temples of the glasses.
[0099] The bracket type is to place the eye drug delivery device on a bracket mechanism; the bracket mechanism includes, but is not limited to: a desktop bracket, a multi-joint mechanical arm bracket, an adsorption bracket and / or a magnetic bracket, etc. Figure 5 As shown, the drug delivery system 2, the control module 3 and the drug storage system 4 form an integrated structure 7, which is disposed on a support mechanism 9. A buckle structure 10 is provided on the top of the integrated structure 7.
[0100] The mounting type is to place the eye medication device on a mounting mechanism; the mounting mechanism includes, but is not limited to, a hook or a hanger. Figure 6 As shown, the drug delivery system 2 , the control module 3 and the drug storage system 4 form an integrated structure 7 , and the mounting mechanism includes, but is not limited to: a hook 11 , and the integrated structure 7 is set on the hook 11 .
[0101] The medical instrument module integration is to set the eye drug delivery device on a medical instrument, which includes, but is not limited to: an ophthalmic surgical device, a nebulizer treatment device, a meibomian gland dysfunction treatment device and / or a smart wearable medical terminal. Figure 7 As shown, the drug delivery system 2 , the control module 3 and the drug storage system 4 form an integrated structure 7 , which is disposed on a medical instrument 12 . The medical instrument 12 has an adsorption area 13 , on which the integrated structure 7 is disposed.
[0102] When the eye drug delivery device is set as a partially internal body type, the part of the eye drug delivery device that is inside the human body is implanted into the human body in the following ways: tissue suture fixation, claw structure embedding, anchoring structure embedding and / or medical glue fixation, etc.
[0103] The drug delivery system 2 provides power to deliver the drug solution. Simultaneously, by adjusting the position of the ocular drug delivery device, a height difference is created between the liquid level in the drug storage system 4 and the eye area. This height difference generates static pressure-assisted drug delivery. The drug storage system 4 includes, but is not limited to, a reservoir. For static pressure-assisted drug delivery, the drug storage system 4 is secured to the patient's head or an area above the eye using a wearable, bracket-like, or mounted structure. This creates a height difference ΔH between the liquid level in the reservoir and the eye area. This height difference ΔH generates a static pressure P = ρgΔH, where ρ is the density of the drug solution and g is the acceleration due to gravity. This pressure is then delivered to the eye area via the drug delivery system 1. In this embodiment, the reservoir of the drug storage system 4 is positioned above the eye. A liquid level sensor is located at the bottom of the reservoir to monitor the liquid level in real time and provide feedback of the ΔH value to the control unit of the control module 3 to ensure the stability of the static pressure-assisted delivery. When the ΔH value falls below a threshold, the control unit triggers an alarm, which indicates that the height adjustment is required. According to other embodiments of the present invention, the liquid reservoir may also be located at a position relatively at the same height as the eyes or at a position lower than the eyes.
[0104] The control device of the ocular drug delivery device controls the drug delivery system 2 in a manner including, but not limited to: wireless remote control, wired connection and / or independent operation to adapt to different usage scenarios and user needs.
[0105] Wireless remote control methods include, but are not limited to, optical communication, acoustic communication, and / or electromagnetic wave communication; communication protocols include, but are not limited to, Bluetooth, Wi-Fi, Zigbee, or Near Field Communication (NFC). Users can establish a wireless connection with the device via a smartphone, tablet, and / or dedicated remote control to remotely set the dosing regimen, adjust parameters, and monitor status.
[0106] According to another embodiment of the present invention, the patient can input a personalized medication plan through mobile phone software under the guidance of a doctor, such as the number of deliveries per day, the duration of each delivery, the start time of delivery, and the alarm threshold, and receive real-time notification of device abnormalities.
[0107] Wired connections include, but are not limited to, physical connections to a terminal device via a serial and / or parallel communication port, or to a host computer via a serial and / or parallel communication port. This wired connection is suitable for batch configuration, data import, or device calibration in medical institutions or clinical settings. Doctors can use wired connections to quickly import standardized treatment plans across multiple devices, improving configuration efficiency and ensuring parameter consistency.
[0108] The control module 3 can also adopt an independent operation mode, in which the control device operates independently under preset parameter conditions without external input, thereby realizing the automatic liquid medicine delivery control function.
[0109] The above-mentioned wireless remote control mode, wired connection and independent operation mode can be supported in parallel, and users can switch freely according to the usage scenario, so as to realize the flexible deployment and efficient use of this device in various application environments such as telemedicine, home management and clinical treatment.
[0110] The drug liquid delivery system 1 includes, but is not limited to, a drug liquid delivery pipeline 101, wherein the two ends of the drug liquid delivery pipeline 101 are respectively connected to a liquid inlet port 102 and a liquid outlet port 103. The drug liquid delivery system 1 is made of a soft biocompatible material. The drug liquid delivery system 1 is made of a material that complies with the "Guidelines for General Requirements for Drug Packaging Materials" of the "Chinese Pharmacopoeia" Drug Packaging Material Standard System 9621. The drug liquid delivery system 1 is made of plastic, metal, glass, ceramic, rubber, and / or other materials. The drug liquid delivery system 1 can be a composite or combination of two or more materials. According to another preferred embodiment of the present invention, the drug liquid delivery system 1 can be made of silicone, rubber, polyurethane, and / or polytetrafluoroethylene.
[0111] The drug delivery system 1 has various shapes, depending on the implant location, path length, physiological curvature, and actual use scenario, to adapt to the diverse anatomy of the human body, improving infusion stability and patient comfort. The drug delivery system 1 can be linear, curved, coil spring, L-shaped, U-shaped, and / or tapered.
[0112] The different shapes of the drug liquid delivery system 1 can be a continuous, integrally formed structure or a modular, discontinuous structure composed of multiple functional segments, each connected by an interface. The interface must ensure the tightness and consistency of the drug liquid pathway and meet safety, hygiene, and ease of operation requirements. Interfaces include, but are not limited to, components or methods for connecting pipes to pipes or pipes to equipment. According to another preferred embodiment of the present invention, interfaces include, but are not limited to, Luer connectors, ferrule connectors, threaded connectors, screw-on connectors, magnetic connectors, and / or medical-grade quick connectors.
[0113] In the drug liquid transmission system 1, the drug liquid transmission pipeline 101 and the liquid outlet port 103 are connected through the nasolacrimal duct adapter 5, and the nasolacrimal duct adapter 5 and the drug liquid transmission pipeline 101 are connected through the interface 6; the nasolacrimal duct adapter 5 enters the body through the nasolacrimal duct-lacrimal sac-lacrimal ductule path to reach the lacrimal punctum. The shape of the nasolacrimal duct adapter 5 matches the direction of the lacrimal duct and is a gradually tapered cone. The drug liquid transmission pipeline 101 and the liquid outlet port 103 can be precisely aligned with the lacrimal punctum opening to realize drug liquid transportation.
[0114] The drug delivery system 2 is the power for delivering the drug. The structure and control method of the drug delivery system 2 can refer to existing mature micro-drug infusion devices, such as insulin pumps. The drug delivery system 2 includes, but is not limited to, at least one pump and / or a mechanical mechanism that can promote the transmission of liquid in the drug delivery system 1. The pumps include, but are not limited to: positive displacement pumps, electric pumps and / or power pumps; positive displacement pumps include, but are not limited to peristaltic pumps, peristaltic metering pumps, diaphragm pumps, gear pumps, syringe pumps, plunger pumps and / or piston pumps; electric pumps include, but are not limited to micro electromagnetic pumps and / or piezoelectric drive pumps; power pumps include, but are not limited to centrifugal pumps and / or vortex pumps. The above pump types can be selected according to the specific application scenario.
[0115] Depending on different clinical needs and individual patient differences, the number of drug delivery systems 2 can be one or more. Multiple drug delivery systems 2 can operate independently or collaboratively to achieve precise drug delivery or improve system reliability. For example, to improve device reliability, the ophthalmic drug delivery device can be configured with a dual-pump system: the main pump performs normal infusion tasks, while the backup pump is in standby mode. When the control module 3 detects an abnormal flow rate or cessation of the main pump, it automatically switches to the backup pump to ensure continuous and uninterrupted drug delivery.
[0116] The drug delivery system 2 can be operated automatically, or the drug delivery system 2 is connected to the control device, and the control device drives the drug delivery system 2 to operate; the connection between the drug delivery system 2 and the control device includes, but is not limited to: wireless connection and / or wired connection;
[0117] Wireless connections include, but are not limited to: optical communication, acoustic wave communication, and / or electromagnetic wave communication;
[0118] The wired connection includes, but is not limited to: a serial communication port and / or a parallel communication port connected to a terminal device, or a serial communication port and / or a parallel communication port connected to a host computer.
[0119] The control device of the control module 3 can send a control signal to the drug delivery system 2 through this connection method to achieve precise adjustment of the infusion flow rate, frequency and time.
[0120] The drug delivery system 2 can be placed inside the control device of the control module 3 according to actual application requirements, forming an integrated structure. This facilitates the miniaturization and integration of the ocular drug delivery device, improving stability and portability. The ocular drug delivery device can also be installed outside the control device of the control module 3, achieving a flexible layout. This design facilitates maintenance and replacement.
[0121] The drug delivery system 2 is arranged inside the control module 3 or outside the control module 3;
[0122] The drug delivery system 2 can be placed inside the control module 3 according to actual application requirements, forming an integrated structure. This facilitates the miniaturization and integration of the entire device, improving stability and portability. The drug delivery system 2 can also be installed outside the control module 3, achieving flexible layout. This design facilitates maintenance and replacement.
[0123] When the drug delivery system 2 is disposed inside the control module 3, the methods of fixing the drug delivery system 2 inside the control module 3 include, but are not limited to: structural bracket fixing, snap slot fixing, screw fixing and / or integral injection molding fixing, so as to ensure that the drug delivery system 2 is stable in position during the operation of the device and avoid vibration interference; Figure 8 As shown, the drug delivery system 2 is arranged on a structural support 14. Figure 9 As shown, the drug delivery system 2 is arranged on the buckle slot 15 .
[0124] When the drug delivery system 2 is arranged outside the control module 3, the drug delivery system 2 can be arranged inside or outside the infusion pool of the drug storage system 4; or the drug delivery system 2 is fixed to the outer surface of the control module 3 by means of a shell slot, a flexible bracket, medical tape, a wearable strap system, a hook structure and / or a magnetic interface; or the drug delivery system 2 is independently arranged, and the drug delivery system 2 is not directly connected to the control module 3 or the drug storage system 4, but works in conjunction with other functional modules through a catheter or an interface to adapt to the flexible deployment requirements of multiple scenarios and facilitate the separate maintenance, replacement or upgrade of the drug delivery system 2. According to another preferred embodiment of the present invention, the drug delivery system 2 is fixed to the outside of the control module 3 by a structural bracket. Figure 10 As shown, the drug delivery system 2 is connected to the control module 3 via the housing slot 16. Figure 11 As shown, the drug delivery system 2 is connected to the control module 3 via a flexible bracket 17 .
[0125] The drug liquid delivery system 2 is directly connected to the drug liquid transmission system 1 , or the drug liquid delivery system 2 is indirectly connected to the drug liquid transmission system 1 .
[0126] The drug delivery system 2 and the drug transmission system 1 are connected in an indirect manner, including but not limited to any of the following:
[0127] C1, the drug delivery system 2 is arranged inside or outside the drug storage system 4, and the drug delivery system 2 indirectly promotes the transportation of the drug by pressurizing the drug;
[0128] C2, the drug delivery system 2 is arranged inside or on the top of the drug storage system 4, and the drug delivery system 2 pushes the drug in the drug storage system 4 into the drug transmission system 1 through a diaphragm structure or a piston structure;
[0129] C3. The drug delivery system 2 uses a pump body, and the driving mechanism applies pressure to the outer wall of the drug transmission system 1. The pump body applies driving force to the inside of the drug transmission system 1, so that the drug in the drug transmission system 1 is propelled and transported.
[0130] When the drug delivery system 2 and the drug transfer system 1 are not directly connected, the drug delivery system 2 is set inside or outside the drug storage system 4, and the drug delivery system 2 pressurizes the drug storage system 4 as a whole, or indirectly pushes the drug into the drug transfer system 1 with the help of a diaphragm structure or a piston structure; or when the drug delivery system 2 is a peristaltic pump, the pump body of the peristaltic pump and the drug transfer system 1 can adopt an external contact drive structure, that is, the roller applies periodic pressure along the outer wall of the drug transfer system 1 to promote the flow of drug in the tube. Figure 12As shown, the medical liquid storage system 4 pushes the medical liquid into the medical liquid transmission system 1 by means of the diaphragm structure 18 .
[0131] The drug delivery system 2 is directly connected to the drug transfer system 1, including but not limited to: a rigid connection, a flexible connection and / or a detachable connection;
[0132] The rigid connection includes, but is not limited to: a snap-fit structure connection, an integrally formed structure connection and / or a fixed shell structure connection; so that the drug delivery system 2 and the drug transfer system 1 form an integrated module, which is suitable for wearable or portable devices;
[0133] The flexible connection includes, but is not limited to: flexible wires, soft liquid medicine catheters and / or plug-in electrical connectors, which realize the functional connection between modules and facilitate flexible layout adjustment or replacement;
[0134] The detachable connection includes, but is not limited to, an interface connection, which facilitates the user to replace, add medicine, or clean and maintain the liquid drug delivery system 2. The interface includes, but is not limited to, a component or method for connecting pipes to pipes or pipes to equipment, which facilitates the user to replace, add medicine, or clean and maintain the liquid drug delivery system 2.
[0135] The control module 3 includes, but is not limited to, a power supply and a control device. The power supply supplies power to the device. The number of power supplies can be one or more according to different clinical use requirements and individual differences of patients.
[0136] The power supply includes, but is not limited to, the main power supply and the backup power supply. Under normal circumstances, the main power supply provides the main power source for the equipment. When the main power supply fails or is interrupted, the backup power supply is started to ensure the normal operation of the equipment.
[0137] The power source includes, but is not limited to: chemical batteries and / or photovoltaic cells, etc.; the chemical batteries include, but are not limited to: primary batteries and / or rechargeable batteries, etc.; the primary batteries include, but are not limited to: zinc-manganese dry batteries and / or lithium-manganese batteries, etc.; the rechargeable batteries include, but are not limited to: lead-acid batteries, lithium-ion batteries and / or nickel-metal hydride batteries, etc.; the photovoltaic cells include, but are not limited to: silicon photovoltaic cells, organic photovoltaic cells and / or compound semiconductor photovoltaic cells, etc.
[0138] The control device includes, but is not limited to, a processor and multiple functional modules, and the multiple functional modules include, but are not limited to: an alarm module, a data recording module, a timer module and / or a user management module; the alarm module, the data recording module, the timer module and / or the user management module are all connected to the processor. When the liquid medicine is exhausted, the battery is low, the pipeline is blocked or the pump is working abnormally, the alarm module will emit an audible, visual or wireless alarm prompt. The data recording module is used to automatically record information such as the time, delivery volume, power usage, etc. of each delivery, and supports data storage and periodic uploading. The timer module is used to set the drug administration cycle, and the timer module includes, but is not limited to the number of doses per day, the duration of each delivery, the delayed start time, etc., and can achieve high-precision timing control. The user management module supports the storage of multiple user profiles, which is convenient for rapid switching and personalized parameter configuration between multiple patients or users.
[0139] The processor is provided with a programming interface, and the control device is used to receive and execute preset parameters or user input instructions. The processor includes, but is not limited to, an integrated chip, an embedded microcontroller, a digital signal processor, a system-on-chip, a programmable logic controller and / or a field programmable gate array. The programming interface of the processor includes, but is not limited to, a user interaction interface, a remote configuration interface and / or a clinical professional interface. The user interaction interface includes, but is not limited to: an LCD display, a button, a touch panel and / or a wireless communication module. The processor is used to display key parameters such as the device operating status, the remaining amount of liquid medicine, alarm information, battery power, etc. to the user in real time, or to allow the user to set medication parameters such as medication time, flow rate, frequency, etc. and to confirm the operation.
[0140] Users can interact through a graphical interface or voice prompts to improve ease of use and safety. Remote configuration interfaces include, but are not limited to: standard communication module interfaces (such as Bluetooth BLE interfaces, Wi-Fi modules, Zigbee module interfaces), mobile communication modules (such as 4G / 5G modules) and / or compatible cloud platform access protocols (such as MQTT, HTTPS, LoRaWAN) and other communication methods;
[0141] The ocular drug delivery device of this embodiment allows the device to establish a data connection with a smart terminal or cloud server, enabling remote configuration, parameter synchronization, medication record upload, device status feedback, and online fault diagnosis. Smart terminals include, but are not limited to, mobile phones, tablets, and computers.
[0142] Medical staff can regularly update medication plans or retrieve historical usage records through the remote background system to achieve remote intervention and closed-loop data management for personalized treatment. Clinical professional interfaces include, but are not limited to: standard communication interfaces (such as RS-232, RS-485, CAN bus), USB interfaces, Type-C interfaces, HL7 or DICOM protocol support interfaces, and docking modules for hospital information systems (HIS), electronic medical record systems (EMR), and / or device management systems (MDMS). This interface is configured for data interaction with professional medical terminals in a clinical environment and can be used to batch configure multiple devices, import standard treatment parameters, export medication records, or calibrate device operating status.
[0143] The drug liquid storage system 4 is made of biocompatible and corrosion-resistant materials. The materials of the drug liquid storage system 4 must comply with the "Guidelines for General Requirements for Drug Packaging Materials" in the "Chinese Pharmacopoeia" drug packaging material standard system 9621.
[0144] The drug storage system 4 is made of plastic, metal, glass, ceramic, rubber, and / or other materials. The drug storage system 4 is composed of a composite or combination of two or more materials. According to another preferred embodiment of the present invention, the drug storage system 4 is made of polypropylene (PP), polyethylene (PE), polycarbonate (PC), and / or a composite multilayer film material.
[0145] The liquid medicine storage system 4 can be a disposable or reusable structure, and the structure of the liquid medicine storage system 4 includes, but is not limited to: a sealed structure, a replaceable liner structure, a flexible liquid storage capsule structure and / or a rigid liquid medicine box structure. Among them, the sealed structure prevents the liquid medicine from being exposed to the air through the overall closed container structure, effectively isolating the pollution source. The replaceable liner structure facilitates the replacement of the internal liquid storage unit while maintaining the stability of the outer shell structure, thereby improving economy and portability. The flexible liquid storage capsule structure is made of highly elastic material and can naturally shrink as the volume of the liquid medicine changes, which is conducive to maintaining a positive or negative pressure delivery environment. The rigid liquid medicine box structure provides stronger physical protection and is suitable for stable use in high-precision medication scenarios or transportation environments.
[0146] The liquid medicine storage system 4 is equipped with a regulation system, which uses valves such as one-way valves, liquid level control valves, micro-check valves, bacterial filter vent valves, and / or automatic opening and closing valves. The regulation system is used to prevent liquid medicine backflow and external environmental contamination, ensure liquid medicine purity and safe delivery, and maintain liquid medicine output stability and system sealing.
[0147] Various valves can be used individually or in combination according to system requirements to achieve safe storage, stable delivery, and intelligent control of liquid medicine. The one-way valve is used to control the flow of liquid medicine only in the outlet direction, preventing external air or liquid from flowing back into the liquid medicine storage system 4, ensuring the unidirectionality of the infusion path and the purity of the liquid medicine. The liquid level control valve is used to automatically open and close the liquid outlet path according to the set liquid level, which can prevent problems such as delivery interruption or pump idling caused by insufficient liquid medicine. The micro-check valve has a built-in micro-elastic structure that opens under normal flow pressure and closes under reverse pressure or static state, improving the sealing and safety of the entire system. The bacterial filter vent valve is equipped with a hydrophobic microporous membrane that can effectively block bacteria or particles while maintaining air permeability, balancing the pressure difference between the inside and outside of the liquid medicine storage system 4, and preventing abnormal liquid medicine delivery due to negative pressure. The automatic opening and closing valve can be set based on time control, flow sensing, or pressure threshold. It automatically opens when the system is running and automatically closes when it is shut down or in an abnormal state to prevent external contaminants from entering the system.
[0148] The liquid storage system 4 is equipped with a liquid sensor for monitoring the remaining volume of the liquid. The liquid sensor includes, but is not limited to, a capacitive sensor, an optical sensor, an ultrasonic liquid level sensor, and / or a pressure sensor. The liquid sensor can convert liquid level changes into electrical signals and transmit them to the control module 3 for processing.
[0149] When the liquid sensor detects that the drug liquid level is below a set threshold, the drug liquid storage system 4 can prompt the user through audio and visual prompts or wireless signals to promptly replace or replenish the drug liquid, thereby ensuring the continuity and safety of the drug delivery process. In some application scenarios, the drug liquid storage system 4 can also be equipped with no liquid sensor, and the user can visually determine the remaining drug liquid level through a transparent or translucent liquid storage structure, thereby simplifying the design and controlling costs.
[0150] The connection between the liquid medicine storage system 4 and the control module 3 includes, but is not limited to: a rigid connection, a flexible connection, a detachable connection and / or a wireless communication control connection;
[0151] The rigid connection includes, but is not limited to: a snap-fit structure, an integrally formed structure and / or a fixed shell structure; the liquid medicine storage system 4 and the control module 3 form an integrated module, which is suitable for wearable or portable devices.
[0152] The flexible connection includes, but is not limited to: flexible wires, soft liquid medicine tubes and / or plug-in electrical connectors; to achieve functional connection between modules, facilitating flexible layout adjustment or replacement. Figure 13 As shown, the drug liquid storage system 4 and the control module 3 are connected via a flexible wire 19 .
[0153] The detachable connection includes, but is not limited to, an interface connection; an interface includes, but is not limited to, a component or method for connecting pipes to pipes or pipes to equipment. The detachable connection facilitates the user to replace, add medicine, or clean and maintain the liquid medicine storage system 4.
[0154] The wireless communication control connection includes, but is not limited to, Bluetooth, NFC, and / or Wi-Fi. The wireless communication control connection enables the control module 3 to remotely interact with sensors or other components in the liquid medicine storage system 4.
[0155] The connection between the liquid medicine storage system 4 and the liquid medicine delivery system 2 includes, but is not limited to, a hose connection, a rigid tube connection, a Luer connector connection, a snap-on connection, a threaded connection, a plug-in connection, a magnetic connection, and / or a quick-connect interface connection. The connection between the liquid medicine storage system 4 and the liquid medicine delivery system 2 allows for fluid-tight transmission while facilitating assembly, disassembly, and replacement, and is suitable for either a disposable structure or a reusable modular design.
[0156] The liquid medicine is a finished drug approved by the Food and Drug Administration, or a hospital preparation that complies with relevant regulations, or a liquid preparation that meets medical use standards.
[0157] The liquid medicine can be a finished drug approved by the Food and Drug Administration, or a hospital preparation that complies with relevant regulations, or other liquid preparation that meets medical use standards.
[0158] Medicinal solutions include, but are not limited to, autologous serum preparations, single drug solutions, or compound drug solutions. Autologous serum preparations are generally not mixed with other medicinal solutions. Single drug solutions include, but are not limited to, a single active ingredient. When the single drug solution is 0.5% levofloxacin eye drops, the 0.5% levofloxacin eye drops have an antibacterial effect; when the single drug solution is 0.1% fluorometholone eye drops, the 0.1% fluorometholone eye drops have an anti-inflammatory effect.
[0159] A compound drug solution includes, but is not limited to, two or more drugs. Both drugs in the compound drug solution are active ingredients and generally work synergistically. When the two drugs in the compound drug solution are levofloxacin and dexamethasone, levofloxacin has an antibacterial effect, and dexamethasone has an anti-inflammatory effect. When the two drugs in the compound drug solution are cyclosporine A and sodium hyaluronate, cyclosporine A has an immunomodulatory effect, and sodium hyaluronate has a moisturizing effect.
[0160] The entire device has a compact structure, and users can set a dosing plan based on their specific condition and doctor's advice to achieve personalized ocular drug management.
[0161] The eye medicine supplement device of the present invention realizes intelligent and precise control of the medicine liquid for delivery to the eye, solving the problems of unstable manual drug administration and poor compliance in the prior art.
[0162] In summary, the present invention effectively overcomes various shortcomings of the prior art and has high industrial utilization value.
[0163] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the present invention. Anyone skilled in the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by one of ordinary skill in the art without departing from the spirit and technical principles disclosed herein are intended to be covered by the claims of the present invention.
Claims
1. An ocular drug delivery device, characterized in that: include: A drug liquid transmission system (1), a drug liquid delivery system (2), a control module (3) and a drug liquid storage system (4); The liquid medicine transmission system (1) comprises a liquid medicine transmission pipeline (101), wherein both ends of the liquid medicine transmission pipeline (101) are respectively connected to a liquid inlet port (102) and a liquid outlet port (103); The liquid medicine storage system (4) is used to store liquid medicine; The drug liquid delivery system (2) provides power for drug liquid delivery; The control module (3) includes a control device and a power supply connected to the control device, wherein the control device is connected to the drug liquid delivery system (2); the control device controls the drug liquid delivery system (2) to drive the drug liquid in the drug liquid storage system (4) to be transported outward through the drug liquid transmission pipeline (101).
2. The ocular drug delivery device according to claim 1, wherein: The eye drug delivery device is arranged in an in vitro, in vivo or partially in vivo manner; the liquid outlet port (103) of the drug delivery pipeline (101) contacts the drug delivery area; The in vitro method is to place the ocular drug delivery device as a whole outside the human body; The in-vivo method is to implant the ocular drug delivery device as a whole into the human body; The partially intracorporeal type is a method in which a portion of the ocular drug delivery device is implanted inside the human body, and the other portion of the ocular drug delivery device is placed outside the human body.
3. The ocular drug delivery device according to claim 2, wherein: When the eye drug delivery device is arranged in an in-vivo or partially in-vivo manner, the drug delivery area contacted by the liquid outlet port (103) of the drug delivery pipeline (101) includes the eye, eye-related tissue area or eye surrounding tissue area; the drug delivery area contacted by the liquid outlet port (103) of the drug delivery pipeline (101) includes: eyelids, lacrimal ducts, lacrimal sacs, lacrimal glands, lacrimal puncta, canthus, palpebral margin, conjunctiva, meibomian gland outlet area and / or corneal limbus peripheral area; When the eye drug delivery device is set up in vitro, the drug delivery area contacted by the liquid outlet port (103) of the drug delivery pipeline (101) includes the eye and eye-related tissue areas; the drug delivery area contacted by the liquid outlet port (103) of the drug delivery pipeline (101) is the eye area.
4. The ocular drug delivery device according to claim 2, wherein: When a portion of the ocular drug delivery device is implanted inside the human body, the tissues through which the ocular drug delivery device is implanted include: the nasal cavity, the nasolacrimal duct, the lacrimal sac, the lacrimal duct, the area behind the ear, the temporal soft tissue, the subcutaneous tissue below the zygomatic bone, the inner side of the upper eyelid, the inner side of the lower eyelid, the lacrimal gland, or the lacrimal punctum entrance.
5. The ocular drug delivery device according to claim 1, wherein The liquid drug delivery method of the ocular drug delivery device includes any one of the following: A1, the drug liquid delivery system (2) provides power to transport the drug liquid; A2. The drug delivery system (2) provides power to transport the drug. At the same time, the position of the eye drug delivery device can be adjusted to form a height difference between the liquid level of the drug storage system (4) and the eye area, and the height difference causes static pressure to assist in drug delivery.
6. The ocular drug delivery device according to claim 5, characterized in that: The drug delivery system (2) provides power to deliver the drug, including any of the following: B1, the drug liquid delivery system (2) is arranged in the drug liquid storage system (4), and the drug liquid delivery system (2) applies pressure to the drug liquid to push the drug liquid out; B2, the drug delivery system (2) pushes the drug solution in the drug storage system (4) into the drug transmission system (1) through a diaphragm structure or a piston structure; B3. The drug delivery system (2) provides driving force, and the drug delivery system (2) delivers the drug to the eye area through the drug transmission system (1).
7. The ocular drug delivery device according to claim 1, wherein: The control device controls the drug delivery system (2) in a manner including: a wireless remote control mode, a wired connection mode and / or an independent operation mode; The wireless remote control method includes: optical communication, acoustic wave communication and / or electromagnetic wave communication; The wired connection method includes: connecting the serial communication port and / or parallel communication port to the terminal device, or connecting the serial communication port and / or parallel communication port to the host computer; The independent operation mode is that the control device operates independently under preset parameter conditions without external input, thereby realizing the liquid medicine delivery control function.
8. The ocular drug delivery device according to claim 1, wherein: The drug liquid delivery system (2) and the drug liquid transmission system (1) are directly connected, or the drug liquid delivery system (2) and the drug liquid transmission system (1) are indirectly connected.
9. The ocular drug delivery device according to claim 1, wherein: The liquid medicine storage system (4) can be a disposable or reusable structure, and the structure of the liquid medicine storage system (4) includes: a sealed structure, a replaceable liner structure, a flexible liquid storage bag structure and / or a rigid liquid medicine box structure.
10. The ocular drug delivery device according to claim 1, characterized in that: The drug solution includes a finished drug approved by the State Food and Drug Administration, a hospital preparation that complies with relevant regulations, or a liquid preparation that meets medical use standards; the drug solution includes an autologous serum preparation, a single drug solution, or a compound drug solution; the single drug solution includes one active ingredient; The compound medicine solution includes two or more medicines.